Rizwan Chaudhrey’s Post

Today, AbbVie announced positive top-line results from their Phase 3 study, SELECT-GCA. Upadacitinib (RINVOQ, 15 mg, once daily), paired with a 26-week steroid taper regimen, achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA) with the safety profile remaining consistent with that in approved indications. Key secondary endpoints were also met, with a larger percentage of patients receiving Upadacitinib with the 26-week steroid taper regiment achieving sustained complete remission compared to placebo, and a lower percentage of patients experienced at least one disease flare through week 52 than placebo. However, the study showed that Upadacitinib 7.5 mg did not meet the primary or any of the secondary endpoints. Read more: https://lnkd.in/ejmhxSRF   #GiantCellArteritis #GCA #Rheumatology #AbbVie

Today, we presented first-time clinical data from the Phase 1 study of trispecific TREAT™ antibody, ISB 2001, showing high overall response rate (ORR), with high response rate and favorable safety profile in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). Notably, no dose-limited toxicities were observed at weekly subcutaneous doses up to 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and no discontinuations due to adverse events. Early results showed an impressive ORR of 83% in heavily pretreated patients treated at active doses (50 µg/kg and above). Read the full release: https://bit.ly/3OKDn1v #ASH24

https://bit.ly/45sSPGQ AL Amyloidosis is a blood desease that is crucial the early diagnosis. Before those patients werent treated whith the same dugs as MM ( Myeloma Múltiple), and nowadays we can afford only one approuved drug, in some countries whith difficulties to get out. Prothena is leading for a drug in Pase III giving to us one more option for ouers patients. #AL #ClinicalTrials #Prothena #SomosAmilo www.amilo.es

Delighted to share our first application of virtual twins with liquid biopsy for precision dosing! #CPT, read the article here: doi.org/10.1002/cpt.3291 👥 Virtual Twin models for individual patients generated by customizing base population PBPK models, utilizing Simcyp, to predict exposure (AUC) of oral midazolam in patients with different grades of renal impairment, enabled model-informed precision dosing, with significant consequences for dose selection/adjustment for individual patients at the point of care!

Machine Learning Model Accurately Predicts Intravenous Immunoglobulin Non-Responders For Kawasaki Disease: By developing the Shizuoka score, which features a new predictive model using machine learning, patients with Kawasaki disease who are non-responders to intravenous immunoglobulin were able to be accurately identified. #finance #pharmacy #lifesciences

In 1L G/GEJC, Osemitamab plus Nivolumab /Chemotherapy produced Claudin18.2 expression dependent increase in both objective response rate and medium progression free survival, regardless of PD-L1 status, as we presented at ASCO 2024 (abstract 4048). This is very encouraging news to first-line G/GEJC patients with Claudin18.2 expression!!

Today we announced the publication of a paper in American Society for Microbiology's Antimicrobial Agents and Chemotherapy. The paper focuses on our Phase 1 #ClinicalTrial evaluating lung pharmacokinetics of our drug candidate, SPR720. SPR720 is an oral candidate for the treatment of nontuberculous mycobacterium pulmonary disease (#NTMPD). Learn more and access the publication here: https://bit.ly/3TSpEZe #InfectiousDiseases

We are pleased to announce that we have activated clinical sites and are initiating enrollment for the Phase 1 trial of ADI-001 in autoimmune diseases!   This follows the U.S. Food and Drug Administration’s (FDA) decision to grant Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV #lupus nephritis (LN) and clearance from FDA to develop ADI-001 in four #autoimmune indications including LN, systemic lupus erythematosus (#SLE), systemic #sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated #vasculitis (AAV).   With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue (characteristics important in autoimmune treatment), ADI-001 is uniquely differentiated with the goal to bring durable remissions and provide an immune reset for various autoimmune conditions. We are inspired by the idea of bringing to #patients a potential paradigm shift in the treatment of autoimmune diseases. To learn more about participating in this #clinicaltrial, visit https://lnkd.in/esC4winc or email clinicaltrials@adicetbio.com. #CART #celltherapy #gammadelta #clinicaltrials #autoimmune #autoimmuneclinicaltrials #biotech #biotechinvesting #biotechresearch #allogeneic #offtheshelf

MASH is the newest area of intervention in metabolic health. Earlier this year, Rezdiffra (resmetirom) was launched, but at $48K a year and with very minimal results, there is still a lot to be desired. #GLP1 are also under the microscope in this space. Lilly released information on their trial this past week- https://lnkd.in/gT88XYuD And more novel therapies to come: https://lnkd.in/gKKQ84h7 https://lnkd.in/gkCZAfkU Lots to watch in this space over the next few years! #Pharmacists #Pharmacybenefits #liver #newdrugapproval #GLP1

#ACR24 Abstracts Now Available: Efficacy, safety, and pharmacokinetics of anti-CD40 antibody in patients with Rheumatoid Arthritis: A phase 2, randomized, placebo-controlled 12-week-treatment proof-of-concept study. View here: https://bit.ly/3YLmvNM